City of Austin

AUSTIN, TX — On Thursday, February 5, Austin City Council approved a 10-year Business Expansion Program agreement with 3billion US, Inc., a rare-disease genomics company establishing its first North American location in Austin. 

The project is expected to create 200 full-time jobs with an average annual salary exceeding $95,000 and generate an estimated $8.1 million in capital investment. Over the 10-year term, the City projects approximately $2.3 million in fiscal benefits, including property tax, sales tax, and utility revenues. In addition, 10% of City property tax revenue generated during the agreement term will support the Childcare Assistance Reserve Fund, with an estimated transfer of $20,637.  

3billion US, Inc. Is the U.S. affiliate of a global life sciences company headquartered in Seoul, South Korea. The company specializes in next-generation sequencing-based testing to support the diagnosis of suspected rate genetic diseases. 

The company’s first-ever U.S. operation includes launching a 12,994-square-foot genetic testing laboratory at 13620 Ranch to Market Road 620 in northeast Austin. The facility is expected to process up to 50,000 genetic tests annually and further strengthen Austin’s growing life sciences sector.  

Under the performance-based agreement, the City will provide a jobs-based incentive of $1,000 per eligible job created, capped at $200,000 over 10 years, contingent upon the company meeting its job creation and compliance requirements. Incentive payments will be verified annual by the City and an independent third party. 

In addition to job creation and capital investment, the company has committed to participating in local job fairs, engaging in community outreach efforts, and designating at least 2% of its construction budget towards procuring art from local Austin artists. Employees will receive competitive benefits, including health and dental insurance, 401(k) options, and childcare flexible spending accounts. 

"When a global company like 3billion chooses to grow in Austin, it’s because we offer talent, infrastructure, and a business climate that supports long-term success,” says Anthony Segura, Deputy Director of Austin Economic Development. “This agreement reflects disciplined economic strategy that delivers real jobs and real returns, while positioning Austin on the global stage to advance the health of our community and beyond.” 

“We are deeply honored by the City of Austin’s approval of the Business Expansion Program and are grateful for the warm welcome as we establish our North American headquarters here in Austin,” says Changwon Keum, CEO of 3billion. “This expansion enables 3billion to bring our high-quality, AI-powered rare genetic disease diagnostic services directly to patients across the United States while creating high-wage jobs for local talent. Beyond delivering these innovative diagnostic solutions, we are committed to being a steadfast partner in the long-term prosperity and development of the Austin community.” 
 

This agreement is facilitated by Austin Economic Development’s Business Expansion Program, a Chapter 380 initiative designed to attract and retain companies that align with Austin’s economic priorities and community benefits.  Businesses interested in applying can visit the Business Incentives website and complete the Inquiry Form to schedule a meeting with staff.

###

About Austin Economic Development 
Austin Economic Development supports business growth, creative industries, and local communities. These programs build an equitable, sustainable economy to improve the lives of all Austin residents. To learn more, subscribe to our newsletter or connect with us @AustinEconDev on Facebook, @AustinEconDev on X, and @AustinEconDev on YouTube.   

About 3billion, Inc.

Founded in 2016, 3billion is a leader in AI-driven rare genetic disease diagnostics. Guided by its "Save 10%" mission, the company empowers the global rare disease community—approximately 10% of the population—to move from accurate diagnosis to effective treatment. Headquartered in Seoul and serving over 70 countries, 3billion is rapidly expanding its global footprint, having doubled its revenue every quarter last year. This year, 3billion is establishing a state-of-the-art genomic laboratory in Austin, Texas, to provide U.S. patients with direct access to its differentiated AI-powered diagnostic services. By expanding into AI-driven drug discovery, the company is realizing its vision of an end-to-end healthcare journey from diagnosis to treatment. Starting in the second half of 2026, 3billion will leverage this Austin hub to collaborate closely with local medical professionals and the community to lead the next era of innovation in precision medicine.